Search results
- 57.87Add to watchlist-2.09 (-3.49%)At close: Fri. Jun 7, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open58.98High60.08Low57.76
- Mkt Cap4.91BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close59.9652 Wk. Low37.5552 Wk. High91.10
What analysts are sayingTop stories7 Biotech Stocks to Put on Your Breakthrough RadarYahoo Finance · 2 weeks agoVertex (VRTX) Outperforms Industry on Rapid Pipeline ProgressYahoo Finance · 3 weeks agoRelated stocks
4 days ago · Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.51) to ($4.44) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based off prior year's report dates.
- Institutional Ownership
Of the 324 institutional investors that purchased CRISPR...
- Options Chain
View the latest CRSP options chain and put and call options...
- Halo
Earnings for Halozyme Therapeutics are expected to grow by...
- Institutional Ownership
Earnings Date May 8, 2024; Forward Dividend & Yield--Ex-Dividend Date--1y Target Est 84.29
A high-level overview of CRISPR Therapeutics AG (CRSP) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
1 day ago · Look out for CRSP's next earnings release expected on August 05, 2024. For the next earning release, we expect the company to report earnings of -$1.37 per share, reflecting a year-over-year...
Feb 14, 2024 · CRISPR Therapeutics (CRSP) is expected to report fourth-quarter and full-year 2023 results on Feb 15, 2024. The company will provide updates on the sales numbers of its gene therapy Casgevy, which was approved for sickle cell disease and beta thalassemia in the US and Europe, and its CAR-T candidates CTX112 and CTX131.
Get the latest Crispr Therapeutics AG (CRSP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
People also ask
When is CRSP's next earnings release?
How much did CRISPR Therapeutics (CRSP) miss the consensus estimate?
How does CRISPR Therapeutics (CRSP) perform in fiscal Q1 2023?
Feb 21, 2023 · ZUG, Switzerland and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022.